Innoviva Inc
INVA
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
203.6% upsideUndervalued by 203.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.58 Billion |
|---|---|
| Enterprise Value | $1.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.02 |
| Beta | 0.38 |
| Outstanding Shares | 74,160,000 |
Return
| Return on Equity | 37.59% |
|---|---|
| Return on Assets | 27.46% |
| Return on Invested Capital | 19.35% |
Valuation & Multiples
| P/E Ratio | 3.15 |
|---|---|
| PEG | -0.63 |
| Price to Sales | 4.34 |
| Price to Book Ratio | 1.21 |
| Enterprise Value to Revenue | 3.23 |
| Enterprise Value to EBIT | 3.94 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 37,900▲ 20.70% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 111.49%▲ 2.45% |
|---|---|
| Total Invested | $1.75B▲ 16.32% |
| Investors Holding | 285▲ 4.00% |
ESG Score
No data
About Innoviva Inc
CEO: Pavel Raifeld Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending (e.g., Medicare/Medicaid). Tax policy directly impacts corporate profitability, and decisions on drug pricing within federal health programs are critical revenue drivers for pharmaceutical companies.
This committee allocates discretionary federal spending. Its subcommittees determine funding for agencies like NIH and FDA, and directly influence government procurement of pharmaceuticals for federal health programs, critically impacting revenue and R&D.
This committee has direct oversight of the FDA (drug approval, safety, manufacturing standards) and NIH (research funding), making it a primary regulatory and funding influence on pharmaceutical companies.
This committee's oversight of antitrust laws and intellectual property (patents) is critical for pharmaceutical companies. Decisions on mergers and patent enforcement directly impact competition, market exclusivity, and business strategies in the sector.